Brazilian success: SynAct Pharma scores positive results with therapy for covid-19

After generating promising results in a phase II trial with the company's anti-inflammatory drug for treating covid-19, SynAct Pharma is looking into the possibility of launching phase III.
Photo: Pilar Olivares/Reuters/Ritzau Scanpix
Photo: Pilar Olivares/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

SynAct Pharma has received encouraging results from the clinical trial which the company launched in April earlier this year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading